The Latest Breaking News from Elevar

Once-Daily Lirafugratinib Wins FDA Approval for Previously Treated Advanced Bile Duct Cancer Driven by FGFR2 Changes

FDA approves lirafugratinib (Lyrfigtu) for advanced bile duct cancer with FGFR2 changes after prior treatment. Who qualifies and key side effects.

Medical Daily · Sep 24

Program helps break barriers for students with intellectual disabilities

DALLAS -- A program at the University of North Texas is addressing the barriers that people with intellectual disabilities face when looking for employment and higher education.

Tribune News Service · Aug 22, 2022